Jaguar Health Inc.

News & Events

Press Releases

In The Media

1. Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

   ACCESS Newswire APR 30, 2025 8:15 AM EDT
   Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the p...
   READ ARTICLE

2. REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

   ACCESS Newswire APR 29, 2025 4:15 PM EDT
   The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disea...
   READ ARTICLE

3. Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

   ACCESS Newswire APR 28, 2025 8:15 AM EDT
   The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disea...
   READ ARTICLE

4. Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

   ACCESS Newswire APR 17, 2025 9:00 AM EDT
   Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug De...
   READ ARTICLE

5. Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

   ACCESS Newswire APR 15, 2025 9:30 AM EDT
   The statistically significant responder analysis results for Mytesi ® (crofelemer) in the P...
   READ ARTICLE

6. Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

   ACCESS Newswire APR 8, 2025 8:30 AM EDT
   Gelclair ® is the company's third commercialized prescription product Oral mucosi...
   READ ARTICLE

7. Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   ACCESS Newswire APR 4, 2025 4:15 PM EDT
   SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. ( NASDAQ...
   READ ARTICLE

8. Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

   ACCESS Newswire APR 1, 2025 4:15 PM EDT
   SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDA...
   READ ARTICLE

9. Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

   ACCESS Newswire MAR 31, 2025 8:00 AM EDT
   The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for pre...
   READ ARTICLE

10. 83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

    ACCESS Newswire MAR 28, 2025 9:00 AM EDT
    Canalevia ® -CA1 (crofelemer delayed-release tablets) is the first and only treatment f...
    READ ARTICLE